Actively Recruiting
Evaluating Safety and Effects of ALN-6400 in Female Adolescents and Adults with Von Willebrand Disease and Heavy Menstrual Bleeding
Led by Alnylam Pharmaceuticals · Updated on 2026-10-26
24
Participants Needed
21
Research Sites
113 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, effectiveness, and pharmacodynamics of multiple doses of ALN-6400 in adolescent and adult female patients who have Von Willebrand Disease VWD and experience heavy menstrual bleeding HMB. This phase 2 study aims to understand how ALN-6400 affects these patients over time, including how well the drug is tolerated and its impact on certain biological markers related to the disease. Participants in this study will receive multiple doses of ALN-6400, which will be given by subcutaneous injection. The study is randomized and triple-blinded, with at least two experimental treatment groups receiving ALN-6400. The treatment period includes monitoring up to 72 weeks to assess the effects and safety of the drug. During the trial, participants will be monitored through various assessments, including tracking the frequency of adverse events, changes in plasminogen plasma activity and protein levels, and menstrual blood loss measured by a pictorial blood assessment chart. Patient-reported outcomes, such as global impressions of change and severity, will also be collected from baseline up to 72 weeks post-dose. Safety and efficacy data will be gathered throughout the study period, which lasts up to approximately three years from start to completion.
CONDITIONS
Brief Title
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here